Updated: 20 hours ago
Medically reviewed by Dr Eric Wang-ChinaCureLink Team
Introduction
China is one of the few countries where patients can receive a personalized therapeutic cancer vaccine outside a clinical trial. Two dendritic cell (DC) vaccines, Neo-DCAct™ and LANEX-DC®, are approved for use in the Hainan Boao Lecheng pilot zone, and Chinese personalized mRNA vaccines are producing early results in major cancer hospitals. In May 2026, a new national regulation also gave cell therapies and tumor vaccines their own legal route from research into clinical use.
A personalized vaccine is built from the patient's own tumor, so the consultation has to happen at the right moment, with the right sample. This guide explains how to book a personalized cancer vaccine consultation in China: which vaccines exist, why timing matters, what to prepare and what the consultation should answer.
Key Takeaways |
|
Table of Contents
Personalized Cancer Vaccines Available in China in 2026
Personalized cancer vaccines are therapeutic, not preventive. They train the immune system to recognize mutations found only in the patient's own cancer, called neoantigens.
The science behind each product is explained in ChinaCureLink's guides to personalized DC vaccine therapy in China and the wider China cancer vaccine landscape.
Why Timing Matters Before Booking
A personalized vaccine starts with sequencing the patient's tumor to find its unique mutations. That needs good-quality tumor tissue, and the best tissue is usually collected at surgery or biopsy.
The neoantigen mRNA vaccine study at Sir Run Run Shaw Hospital, led by Academician Cai Xiujun, shows why this matters. The study requires patients to be assessed and enrolled before surgery, so fresh tumor tissue from the operation can be kept for sequencing and vaccine design. Once tissue has gone through routine pathology processing, part of its genetic information can be damaged.
In a case reported by the hospital in June 2026, a pancreatic cancer patient who had already had surgery elsewhere a month earlier asked to join, and had missed the window. The study has since expanded from three cancers to six: pancreatic, liver, biliary, esophageal, gastric and colorectal cancer.
Not every program works this way. Neo-DCAct™ at West China Lecheng Hospital accepts surgical tumor tissue from the past two years, or a new biopsy or surgical sample. But the lesson is the same: the best time to book a personalized cancer vaccine consultation is before the next surgery or biopsy, not after it.
Who May Be a Candidate
Each program sets its own criteria. Common requirements across the Chinese programs include:
A solid tumor confirmed by pathology, of a type the program accepts
Usable tumor tissue, either stored or newly collected
Good general health, usually an ECOG performance status of 0 to 1
Stable disease, with expected survival longer than the time needed to make the vaccine
Adequate blood counts and liver and kidney function
For Neo-DCAct™, candidates generally have had no more than two previous lines of systemic treatment. The vaccine is registered for use after surgery to lower the risk of recurrence, or after standard treatment for locally advanced or inoperable tumors.
Patients are usually not suitable if they have an active autoimmune disease or infection, severe immunodeficiency, long-term high-dose steroids or immunosuppressants, a rapidly progressing tumor, or no usable tumor tissue.
Records and Tumor Samples to Prepare
Moving tumor tissue between countries needs special handling, and some programs prefer a new sample taken in China. This is one of the first practical points to settle at the consultation.
What a Cancer Vaccine Consultation Should Answer
A well-prepared consultation should end with clear answers to these questions:
Is the vaccine approved for use in the Boao Lecheng pilot zone, or is it a clinical trial?
Is the patient's existing tumor tissue usable, or is a new sample needed?
How long does manufacturing take, and what treatment continues meanwhile?
How many doses are planned, on what schedule, and how long must the patient stay in China?
Will the vaccine be combined with another treatment, such as PD-1 immunotherapy?
How will the response be monitored after the patient returns home?
A personalized vaccine works alongside standard treatment such as surgery, chemotherapy or immunotherapy. It does not replace it, and no vaccine guarantees a cure.
Case Studies: Personalized Vaccines in Chinese Hospitals
The First Neo-DCAct™ Patient in Boao Lecheng
In April 2025, West China Lecheng Hospital gave Neo-DCAct™ to its first patient, who was recovering from lung cancer surgery. The vaccine was designed from the mutations in the patient's own tumor and given to help the immune system clear any cancer cells left after the operation. The timing, right after surgery with tissue in hand, is exactly what the consultation is meant to plan.
A Pancreatic Cancer Patient Who Booked Before Surgery
In 2023, a pancreatic cancer patient traveled from northeast China to Sir Run Run Shaw Hospital after learning about its neoantigen mRNA vaccine study. He was assessed before his operation, so fresh tumor tissue was kept during surgery and used to make his vaccine. After standard chemotherapy combined with the vaccine, the hospital reported in 2026 that his recent check-up showed no tumor recurrence.
Early Results From EVM16
In the first-in-human EVM16 study at Peking University Cancer Hospital and Fudan University Shanghai Cancer Center, 8 of 9 patients with advanced solid tumors developed tumor-specific T-cell responses. One patient with gastroesophageal junction cancer, after three earlier lines of treatment, had a confirmed partial response. Trial access is covered in ChinaCureLink's guide on how to apply for cancer vaccine clinical trials in China.
How International Patients Can Book a Cancer Vaccine Consultation in China
1. Through ChinaCureLink, the dedicated international patient pathway. ChinaCureLink represents the patient, not a hospital or vaccine maker, and takes no hospital commission. There is no fee to apply to hospitals. After a free advisory call, ChinaCureLink checks the patient's tissue, timing and treatment history, then identifies and compares up to three suitable programs or hospitals, including the Boao Lecheng pilot zone hospitals and trial centers. The patient chooses one, and ChinaCureLink arranges a video second opinion with that team. If the patient proceeds, ChinaCureLink coordinates the appointment, records and translation, sample logistics with the hospital, treatment planning, travel and support in China.
2. Directly through the Boao Lecheng hospitals. Patients can submit records to the international departments of West China Lecheng Hospital (Neo-DCAct™) or Boao Super Hospital (LANEX-DC®) for review.
3. Through a trial site. Patients can contact investigators at hospitals running vaccine studies, subject to each study's rules on international enrolment.
Patients who also need a general oncology opinion can follow ChinaCureLink's guide to how to book an oncology appointment in China.
What to Expect When Booking Directly
Pilot-zone access only. Neo-DCAct™ and LANEX-DC® are approved for use inside the Boao Lecheng pilot zone, not for nationwide prescription in China.
Timing gaps. A hospital may not know a patient's surgery date abroad, and the window to keep fresh tissue can close before the review is complete.
Sample logistics. Shipping tissue across borders, or arranging a new biopsy in China, has to be planned with the hospital in advance.
Chinese-language process. Records, consent forms and reports are usually in Chinese.
Telling legitimate programs apart. Since 1 May 2026, under State Council Order 818, clinical research on new biomedical technologies such as tumor vaccines may only be carried out in top-grade (Grade 3A) hospitals with academic and ethics committees. Patients should be cautious of clinics outside this system that offer "personalized vaccines".
ChinaCureLink replies to new case enquiries within 10 minutes. A preliminary case review checks whether the patient's tumor tissue, timing and treatment history fit a Chinese personalized vaccine program, before any surgery date or travel is fixed.
You may also like:
Get a Second Opinion
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Frequently Asked Questions
Can foreigners get a personalized cancer vaccine in China?
Yes. International patients can apply for Neo-DCAct™ or LANEX-DC® in the Boao Lecheng pilot zone after a review of their records by the hospital team. Some vaccine trials may also accept foreign patients, depending on each trial's rules.
When should I book a personalized cancer vaccine consultation?
Ideally before the next surgery or biopsy. Some programs need fresh tumor tissue collected at surgery, and patients who book afterwards can miss the window.
Do I need tumor tissue for a personalized cancer vaccine?
Yes. Every personalized vaccine is designed from the patient's own tumor mutations, so usable stored tissue or a new sample is required.
Is a personalized cancer vaccine a cure?
No. Personalized vaccines train the immune system against the patient's cancer and are used alongside standard treatment. Results so far come mainly from early studies and real-world use in the pilot zone.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
References
ChinaCureLink. China Cancer Vaccine 2026: Approved Options, Trials, Eligibility and Access. https://www.chinacurelink.com/post/china-cancer-vaccine
Hangzhou News. Patients with six digestive cancers can access custom vaccines, 24 June 2026. https://hznews.hangzhou.com.cn/kejiao/content/2026-06/24/content_9244080.htm
State Council of the PRC. Order No. 818: Regulations on the Administration of Clinical Research and Clinical Translation of Biomedical New Technologies, 2025 (effective 1 May 2026). https://www.ncsti.gov.cn/zcfg/flfg/202510/t20251011_221539.html
Yicai. Analysis of Order 818 and Order 828, 2026. https://www.yicai.com/news/103141448.html
MedTech Spectrum. Everest Medicines announces positive first-in-human data for personalised mRNA cancer vaccine EVM16 at AACR 2026. https://www.medtechspectrum.com/news/65/25482/everest-medicines-announces-positive-first-in-human-data-for-personalised-mrna-cancer-vaccine-evm16-at-aacr-2026.html
BioSpace. China's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical trial approval, 2023. https://www.biospace.com/china-s-first-personalized-neoantigen-targeted-cancer-vaccine-receives-nmpa-s-clinical-trial-approval
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
